Chairman Charles E. Grassley, right, and ranking member Sen. Ron Wyden are seen before a Senate Finance Committee on drug pricing in America on February 26, 2019. (Tom Williams/CQ Roll Call)
Both the House and the Senate have competing bills aimed at addressing the rising costs of prescription drugs, a legislative priority backed by President Donald Trump.
But what would these various proposals accomplish, and how likely is it they’ll be signed into law?
[jwp-video n=”1″]
Recent Stories
Race for Platner alternative takes shape
Trump: Definitely not signing bipartisan housing bill
Government-seeded accounts could test Trump’s ‘communists’ claim
After Thursday night firings, election commission has no members
CBO: House highway bill would widen trust fund deficit
As Trump threatens the Smithsonian, Congress is on the sidelines